Dynex Technologies said on Wednesday that it completed a successful field trial of its M² Multiplexed Microwell system, which tests for five diseases with a single process.
The process tests for measles, mumps, rubella, varicella and tetanus, all of which are significant factors in child mortality and congenital deformation in unborn children.
The test was developed as part of a program in the Democratic Republic of the Congo. The process will be used to create a nationwide immunity profile that will be used in the development of immunization programs. The program will survey 40,000 people and test 8,000 children for MMRVT immunity.
"The M² technology from Dynex proved itself very adaptable to the conditions of the samples and the environment in a low resource logistically challenging location like Kinshasa allowing us to achieve our goals of obtaining high quality results quickly easily and inexpensively with a minimum amount of training," Dr. Anne Rimoin of UCLA said.
Dynex President Adrian Bunce said on-site tests completed during the summer proved the process to be robust and easy to use.
"We look forward to launching this fully automated multiplex technology in 2014 for any immunoassay application requiring increased throughput and lower cost per test," Bunce said.
The M² project is funded by the Bill and Melinda Gates Foundation in partnership with UCLA and the Kinshasa School of Public Health.